ICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E

Simply Wall St.07:18

ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656461223?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2026-08-03 07:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656461223","market":"us","top_or_hot":-1,"title":"ICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E","media":"Simply Wall St.","content":"<div>\n<p>ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-icui/icu-medical/news/icu-medical-icui-could-be-2-undervalued-as-recall-questions\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nICU Medical (ICUI) Could Be 2% Undervalued As Recall Questions Meet A Full P E\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-03 07:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-icui/icu-medical/news/icu-medical-icui-could-be-2-undervalued-as-recall-questions><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-icui/icu-medical/news/icu-medical-icui-could-be-2-undervalued-as-recall-questions\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-icui/icu-medical/news/icu-medical-icui-could-be-2-undervalued-as-recall-questions","article_id":"2656461223","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-icui/icu-medical/news/icu-medical-icui-could-be-2-undervalued-as-recall-questions","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656461223","pubTimestamp":1785712701,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed dosing volumes.\nSee our latest analysis for ICU Medical.\nThe US Food and Drug Administration recall news lands against a backdrop of strong recent momentum in ICU Medical's share price, with a 30 day share price return of 13.51% and a 1 year total shareholder return of 32.27%, even as the 5 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","BK4082":"医疗保健设备","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","CDIG":"City Different Investments Global Equity ETF","SG9999015978.USD":"利安颠覆性创新基金A","ICUI":"ICU医疗","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","ICU":"SeaStar Medical Holding Corporation","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD"},"translate_title":"ICU Medical (ICUI) 可能被低估 2%，因为召回问题满足完整的 P E","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICU":1.5,"CDIG":0.61,"ICUI":1.5},"content_text":"ICU Medical (ICUI) is in focus after US regulators published enforcement reports on voluntary Class II recalls of its Plum Duo and Plum Solo infusion pumps, citing a software issue affecting displayed dosing volumes. See our latest analysis for ICU Medical. The US Food and Drug Administration recall news lands against a backdrop of strong recent momentum in ICU Medical's share price, with a 30 day share price return of 13.51% and a 1 year total shareholder return of 32.27%, even as the 5 year total shareholder return is down 12.82%. If this kind of product focused story has your attention, it could be a good moment to broaden your search using our healthcare focused screener for 41 healthcare AI stocks ICU Medical has rallied hard in recent months even as the pump recalls stay in the headlines. Does it make more sense to accept today’s price, or to wait for a cleaner entry point once the valuation work is clear? AdvertisementMost Popular Narrative: 2.3% Undervalued ICU Medical's most followed narrative points to a fair value of $172.50, which sits only slightly above the latest close at $168.51. That small gap keeps the focus squarely on the quality of the assumptions behind the story rather than a big valuation disconnect.  The multiyear replacement cycle for ICU Medical's large installed base of infusion pumps is only now beginning, with refresh and value-capture opportunities expected to meaningfully contribute to revenue growth and recurring cash flows starting next year. Positive forward looking catalyst for both top line and earnings.  Read the complete narrative. Want to see what sits behind that pump replacement theme? The narrative leans on measured revenue growth, rising margins, and a future earnings multiple that needs real follow through. Curious how those moving parts combine to support the fair value. Result: Fair Value of $172.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, ICU Medical's story can quickly shift if regulatory scrutiny around recalls escalates, or if tariff and integration costs weigh more heavily on margins than expected. Find out about the key risks to this ICU Medical narrative. Another View: ICU Medical Through The Earnings Lens The first story around ICU Medical leans on a fair value of $172.50 and a modest 2.3% discount to the current share price. Yet on a simple earnings lens, the stock trades on a P/E of 90.9x, well above the US Medical Equipment industry on 28.8x and peers on 31.7x. The fair ratio sits at 32.8x, so the current multiple is almost three times the level the market could move towards. That gap points to meaningful valuation risk if sentiment cools or if future results fall short of expectations. Which valuation story do you place more weight on? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ICUI P/E Ratio as at Aug 2026Next Steps With ICU Medical drawing strong reactions on both risks and potential rewards, it may be useful to move quickly and review the numbers yourself. To get a balanced view before sentiment shifts again, check the 3 key rewards and 3 important warning signs Looking for more ICU Medical style investment ideas? If ICU Medical has sharpened your focus, do not stop here. Use targeted stock lists to spot opportunities that match your goals before the crowd catches on.  Target long term compounding potential with our list of companies trading below estimated value through the 55 high quality undervalued stocks Prioritise resilience by scanning for companies with low risk scores using the 81 resilient stocks with low risk scores Hunt for promising under followed opportunities by checking the screener containing 19 high quality undiscovered gems   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656461223","isCrawlerRequest":true}